GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO

Watchlist Manager
GlaxoSmithKline Pharmaceuticals Ltd Logo
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Watchlist
Price: 2 759.9 INR 0.61% Market Closed
Market Cap: 467.6B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one GLAXO stock under the Base Case scenario is 1 824.18 INR. Compared to the current market price of 2 759.9 INR, GlaxoSmithKline Pharmaceuticals Ltd is Overvalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GLAXO Relative Value
Base Case
1 824.18 INR
Overvaluation 34%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

12.6
P/S
P/S
Price to Sales
12.6
vs History
11
vs Industry
11
Median 3Y
8.1
Median 5Y
7.9
Industry
2.4
Forward
12.1
More Details
54.4
P/E
P/E
Price to Earnings
54.4
vs History
42
vs Industry
7
Median 3Y
38.6
Median 5Y
49.9
Industry
20.5
Forward
51
More Details
48.1
P/OCF
P/OCF
Price to OCF
48.1
vs History
31
vs Industry
8
Median 3Y
47.9
Median 5Y
44.5
Industry
15.6
More Details
48.1
P/FCFE
P/FCFE
Price to FCFE
48.1
vs History
46
vs Industry
11
Median 3Y
49.1
Median 5Y
47.5
Industry
23.1
More Details
28
P/B
P/B
Price to Book Value
28
vs History
3
vs Industry
1
Median 3Y
16.8
Median 5Y
17.2
Industry
2
More Details
12
EV/S
EV/S
Enterprise Value to Sales
12
vs History
12
vs Industry
11
Median 3Y
7.3
Median 5Y
7.5
Industry
2.5
Forward
11.5
More Details
19.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
19.4
vs History
12
vs Industry
10
Median 3Y
13
Median 5Y
12.9
Industry
4.9
More Details
43.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
43.2
vs History
19
vs Industry
8
Median 3Y
30.6
Median 5Y
36
Industry
12.3
Forward
38
More Details
43.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
43.2
vs History
23
vs Industry
9
Median 3Y
31.6
Median 5Y
38.8
Industry
15.5
Forward
41
More Details
45.9
EV/OCF
EV/OCF
Enterprise Value to OCF
45.9
vs History
28
vs Industry
9
Median 3Y
45.2
Median 5Y
41
Industry
14.1
More Details
45.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
45.9
vs History
41
vs Industry
11
Median 3Y
45.6
Median 5Y
44.9
Industry
17.5
More Details
48.2
EV/IC
EV/IC
Enterprise Value to IC
48.2
vs History
6
vs Industry
2
Median 3Y
24.4
Median 5Y
18.3
Industry
1.8
More Details

Multiples Across Competitors

GLAXO Competitors Multiples
GlaxoSmithKline Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
467.5B INR 12.6 54.4 43.2 43.2
US
Eli Lilly and Co
NYSE:LLY
696.2B USD 14.2 62.7 33.8 36.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371B USD 4.2 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.7
CH
Roche Holding AG
SIX:ROG
204.9B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
178.1B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
158.8B GBP 3.8 27.2 130.4 196.6
US
Merck & Co Inc
NYSE:MRK
191.1B USD 3 11 8.2 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
116.5B EUR 1.3 9.2 5.1 5.9
P/E Multiple
Earnings Growth PEG
IN
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Average P/E: 26.9
54.4
26%
2.1
US
Eli Lilly and Co
NYSE:LLY
62.7
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.2
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Average EV/EBITDA: 397.5
43.2
17%
2.5
US
Eli Lilly and Co
NYSE:LLY
33.8
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.3
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.4
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.1
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Average EV/EBIT: 1 700.5
43.2
18%
2.4
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
14%
1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.6
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
GLAXO intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLAXO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLAXO stock valuation using valuation multiples.
Wall Street Estimates
GLAXO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLAXO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.